Breakthroughs in neurology, oncology, and women’s health highlight Tehran pharmaceutical expo
Three new domestically developed pharmaceutical products were unveiled at the 10th Iran Pharma Exhibition 2025, highlighting advances in neurology, oncology, and women’s health.
The event, held in Tehran, drew senior officials and industry leaders from the country’s pharmaceutical sector, according to the Communications and Information Center of the Iranian Vice-President’s Office for Science, Technology and Knowledge-Based Economy.
Qasemali Ashofteh, CEO of a knowledge-based pharmaceutical group, introduced the products, describing them as the result of extensive research and development efforts aimed at addressing key medical needs.
The first product, marketed under the brand name “Atonce” (generic: lisdexamfetamine mesylate), was developed by Faran Shimi. It targets neurological disorders and is designed for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe binge eating disorder (BED).
The second product, “Albociclib” (generic: palbociclib), produced by Abyan Pharmed, is an oral capsule used in the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative. It selectively inhibits CDK4 and CDK6 enzymes, slowing cancer cell growth.
The third launch, “ACTiAID for Women,” is a fertility supplement from Abyan Darou. Combining myo-inositol and D-chiro-inositol in a clinically specific ratio, it is designed to improve egg quality, regulate menstrual cycles, and boost the success rate of IVF treatments.
Ashofteh emphasized that the group remains committed to innovation and expanding its product pipeline to meet domestic health needs and increase export capacity.
